ATH 0.00% 0.4¢ alterity therapeutics limited

Looks like this new study is Prof. Claassen's product. This 15...

  1. 2,816 Posts.
    lightbulb Created with Sketch. 986
    Looks like this new study is Prof. Claassen's product. This 15 cases are studied in Vanderbilt University Medical Center, where the bioMUSE study was done and now it is also one center for the main phase 2 study. So they very likely have MSA patients which did not meat inclusion criteria for bioMUSE study neither for the original phase 2 study, because they were too old for them. Claassen has been planing the phase 2 protocol with Stamler et al and they have all systems and devices to do this additional open-label biomarker study without a control group. In fact, biomarkers have demonstrated to be quite good in measuring disease activity.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.4¢
Change
0.000(0.00%)
Mkt cap ! $18.62M
Open High Low Value Volume
0.3¢ 0.4¢ 0.3¢ $4.887K 1.626M

Buyers (Bids)

No. Vol. Price($)
49 57693670 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 125241201 25
View Market Depth
Last trade - 10.38am 02/09/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.